Nuo and Nord are expected to achieve four consecutive increases as the FDA approves their oral version of Wegovy.

Novo Nordisk rose 2.5% in early trading on Wednesday and is likely to record a fourth consecutive day of gains. The company received approval in the United States to launch the daily Wegovy oral medication for the treatment of obesity, expanding its range of GLP-1 drugs and intensifying competition with Eli Lilly before a wider market.